Cannabis Compounds Show Promise Against Five Currently Untreatable Brain Diseases

The review presents evidence supporting cannabis-based interventions for intractable epilepsy, brain tumors, Parkinson disease, Alzheimer disease, and traumatic brain injury/CTE. These conditions share some pathological processes that may respond to cannabinoid mechanisms including CB1, CB2, PPARgamma, and 5-HT1A receptor activity.

Narrative review synthesizing basic science and clinical evidence for cannabinoid-based treatments across five neurological conditions, examining multiple cannabis compounds and their mechanisms of action.

Neurology has largely been limited to symptomatic treatment of neurodegenerative diseases. This review argues that cannabis compounds may offer something more ambitious: the potential to slow, arrest, or even reverse pathological processes rather than just managing symptoms.

The multi-target nature of cannabis compounds may be an advantage rather than a limitation in treating complex neurological diseases. This "polypharmaceutical" approach contrasts with the single-target model that has dominated drug development.

Narrative review by a prominent cannabis medicine advocate. Much of the evidence is preclinical or from small studies. The breadth of conditions covered limits depth of analysis for any single disease.